Related Experiment Video

Updated: May 18, 2026

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

The Key to Unlocking the Chemotherapeutic Potential of PPARγ Ligands: Having the Right Combination

Graham Skelhorne-Gross1, Christopher J B Nicol

  • 1Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada K7L 3N6.

PPAR Research
|September 12, 2012
PubMed

Insights

PPARγ ligand combination therapy shows significant promise in cancer treatment, enhancing apoptosis and reducing tumor burden compared to monotherapy. This approach offers a potent strategy for managing various cancers.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Peroxisome proliferator-activated receptor (PPAR)γ activation shows preclinical anti-tumorigenesis effects.
  • PPARγ ligand monotherapy has yielded modest clinical success in cancer treatment.
  • Combination therapies involving PPARγ ligands have demonstrated promising results.

Purpose of the Study:

  • To review and consolidate existing literature on PPARγ ligand combination therapy in cancer.
  • To evaluate the efficacy of combining PPARγ ligands with other agents versus monotherapy.
  • To explore mechanisms underlying the protective effects of PPARγ ligands in cancer treatment.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of combination therapy regimens including chemotherapeutic agents, RXRα agonists, statins, and signaling molecules.
  • Examination of studies reporting synergistic/additive effects on apoptosis, differentiation, cell growth, and tumor burden.

Main Results:

  • Combination therapy with PPARγ ligands demonstrates synergistic/additive effects on apoptosis and differentiation.
  • Combined treatments effectively reduce cell growth and tumor burden.
  • PPARγ ligand pretreatment can overcome drug resistance and reduce treatment toxicities.

Conclusions:

  • PPARγ ligands show significant benefits when used in combination with other agents for cancer treatment.
  • Combination therapy represents a strong therapeutic strategy for managing various cancers.
  • Further investigation into PPARγ ligand combinations is warranted for improved cancer management.

More Related Videos

Optimizing the Genetic Incorporation of Chemical Probes into GPCRs for Photo-crosslinking Mapping and Bioorthogonal Chemistry in Live Mammalian Cells14:02

Optimizing the Genetic Incorporation of Chemical Probes into GPCRs for Photo-crosslinking Mapping and Bioorthogonal Chemistry in Live Mammalian Cells

Published on: April 9, 2018

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...